Canada· CA-DIN-02363356
EMEND IV
A other antiemetics product containing fosaprepitant (fosaprepitant dimeglumine), registered in Canada by MERCK CANADA INC. The same ATC class is registered in 5 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Fosaprepitant (fosaprepitant dimeglumine) is registered in 5 of 19 countries.
Countries holding a registration under ATC A04AD (other antiemetics), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 3 of them publish a price we can compare per daily dose
Fosaprepitant (fosaprepitant dimeglumine) · ATC A04AD
5 / 19 countries
- Canada
- Czechiaprice
- Ireland
- Polandprice
- Switzerlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)
- Manufacturer
- MERCK CANADA INC
- Country
- Canada (CA)
- ATC code
- A04AD
- ATC class
- Other antiemetics
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fosaprepitant (fosaprepitant dimeglumine) in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainFOSAPREPITANT ACCORD 150 MG POLVO PARA SOLUCION PARA PERFUSION EFGAccord Healthcare S.L.U.
- NorwayFosaprepitant accordAccord
- GermanyFosaprepitant AmaroxAmarox Pharma Gmbh
- SwedenFosaprepitant Accord 150 mg Pulver till infusionsvätska, lösningAccord Healthcare B.V.
- United KingdomFosaprepitant 150mg powder for solution for infusion vialsAmarox Ltd
- NetherlandsFosaprepitant Amarox 150 mg, poeder voor oplossing voor infusieAmarox Pharma B.V.
- United StatesfosaprepitantMylan Institutional LLC
- Japanホスアプレピタントメグルミン日本化薬
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Austria · Fosaprepitant Accord, Fosaprepitant Hikma
- Germany · Fosaprepitant Amarox, Fosaprepitant Hikma
- Spain · Fosaprepitant Accord, Fosaprepitant Hikma
- Finland · Fosaprepitant Accord
- United Kingdom (Northern Ireland) · Fosaprepitant Accord Healthcare, Fosaprepitant Amarox
- Iceland · Ivemend
- Italy · Fosaprepitant Accord, Fosaprepitant Hikma
- Liechtenstein · Ivemend
- Netherlands · Fosaprepitant Amarox
- Norway · Fosaprepitant Accord, Ivemend
- Portugal · Fosaprepitant Accord, Fosaprepitant Farmoz
- Sweden · Fosaprepitant Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/12913be8-5c32-40e4-9cc8-7d22cd35ae05 GET /v1/drugs/12913be8-5c32-40e4-9cc8-7d22cd35ae05?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02363356",
"form": "POWDER FOR SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A04AD",
"schedule": [
"Prescription"
],
"drug_code": "84835",
"strengths": [
"150 MG"
],
"ahfs_class": null,
"substances": [
"FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)"
],
"product_categorization": null
}See everything about fosaprepitant (fosaprepitant dimeglumine).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.